LAVA Therapeutics NV Forecast, price target & analysts
LAVA Therapeutics NV Target price 2025 - Analyst rating & recommendation
LAVA Therapeutics NV Classifications & Recommendation:
LAVA Therapeutics NV Price Target
| Target Price | $2.17 |
| Price | $1.29 |
| Potential |
67.96%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target LAVA Therapeutics NV 2026 .
The average LAVA Therapeutics NV target price is $2.17.
This is
67.96%
register free of charge
$3.00
132.56%
register free of charge
$1.50
16.28%
register free of charge
|
|
| A rating was issued by 4 analysts: 1 Analysts recommend LAVA Therapeutics NV to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the LAVA Therapeutics NV stock has an average upside potential 2026 of
67.96%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.77 | 7.75 |
| 65.09% | 14.41% | |
| Net Margin | -609.91% | -373.51% |
| 265.58% | 38.76% |
4 Analysts have issued a sales forecast LAVA Therapeutics NV 2024 . The average LAVA Therapeutics NV sales estimate is
This results in the following potential growth metrics:
2 LAVA Therapeutics NV Analysts have issued a net profit forecast 2024. The average LAVA Therapeutics NV net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2023 | -609.91% | 265.58% |
|---|---|---|
| 2024 |
-373.51%
38.76%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.57 | -1.10 |
| 27.64% | 29.94% | |
| P/E | negative | |
| EV/Sales | negative |
2 Analysts have issued a LAVA Therapeutics NV forecast for earnings per share. The average LAVA Therapeutics NV <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the LAVA Therapeutics NV stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -5.26 | 8.23% |
|---|---|---|
| 2024 |
-4.99
5.08%
Unlock
|
|
P/S ratio
| Current | 4.62 | 23.17% |
|---|---|---|
| 2024 |
4.38
5.11%
Unlock
|
|
LAVA Therapeutics NV...
Current LAVA Therapeutics NV Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 20 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Dec 12 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Dec 11 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Aug 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Aug 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
